Amylyx Pharmaceuticals (AMLX)
(Real Time Quote from BATS)
$2.16 USD
0.00 (0.00%)
Updated Sep 4, 2024 11:20 AM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Amylyx Pharmaceuticals, Inc. (AMLX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.25 | $8.00 | $3.00 | 96.76% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Amylyx Pharmaceuticals, Inc. comes to $4.25. The forecasts range from a low of $3.00 to a high of $8.00. The average price target represents an increase of 96.76% from the last closing price of $2.16.
Analyst Price Targets (6 )
Broker Rating
Amylyx Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 2.71 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.71 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, one is Strong Buy, representing 14.29% of all recommendations. A month ago, Strong Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AMLX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.71 | 2.71 | 2.71 | 2.71 | 2.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/12/2024 | Goldman Sachs | Corinne Johnson | Hold | Hold |
6/24/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/18/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Hold |
3/11/2024 | SVB Securities | Marc Goodman | Strong Buy | Hold |
3/11/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Hold |
3/8/2024 | Evercore Partners | Umer Raffat | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.71 |
ABR (Last week) | 2.71 |
# of Recs in ABR | 7 |
Average Target Price | $4.25 |
LT Growth Rate | 65.00% |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 253 |
Current Quarter EPS Est: | -0.47 |